✦ LIBER ✦

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology

✍ Scribed by Marwan Sabbagh; Jeffrey Cummings

Book ID: 115009343
Publisher: BioMed Central
Year: 2011
Tongue: English
Weight: 147 KB
Volume: 11
Category: Article
ISSN: 1471-2377
DOI: 10.1186/1471-2377-11-21

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Donepezil treatment in patients with mod

Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress

✍ Bruno Vellas; Howard Feldman; Serge Gauthier; Jane Hecker; Ponni Subbiah; Ed Wha 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 191 KB

Tolerability of switching from donepezil

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease

✍ Gunhild Waldemar; Maritta Hyvärinen; Mette Krog Josiassen; Alex Kørner; Heikki L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving

Efficacy and Safety of Donepezil 23 mg v

Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimers Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine

✍ Doody, Rachelle S.; Geldmacher, David S.; Farlow, Martin R.; Sun, Yijun; Moline, 📂 Article 📅 2012 🏛 S. Karger AG 🌐 English ⚖ 458 KB

Specific Functional Effects of Memantine

Specific Functional Effects of Memantine Treatment in Patients with Moderate to Severe Alzheimer’s Disease

✍ Doody, R.; Wirth, Y.; Schmitt, F.; Möbius, H.J. 📂 Article 📅 2004 🏛 S. Karger AG 🌐 English ⚖ 222 KB

Amisulpride in the treatment of behaviou

Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease

✍ M. Mauri; A. Mancioli; V. Rebecchi; S. Corbetta; C. Colombo; G. Bono 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

PND10 COST-EFFECTIVENESS STUDY IN PATIEN

PND10 COST-EFFECTIVENESS STUDY IN PATIENTS WITH MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE: PROJECTED BENEFITS OF DONEPEZIL IN THE UNITED KINGDOM

✍ D Getsios; S Blume; KJ Ishak; G MacLaine 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB